20.500.12556/RUL-137254 Targeting angiogenesis in squamous cell carcinoma of the head and neck opportunities in the immunotherapy era Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition. angiogenesis immunotherapy tumor microenvironment VEGF SCCHN angiogeneza imunoterapija tumorsko mikrookolje true false true Angleški jezik Slovenski jezik Članek v reviji 2022-06-08 11:32:34 2022-06-08 11:32:35 2022-09-15 04:14:51 0000-00-00 00:00:00 2022 0 0 10 str. iss. 5, art. 1202 Vol. 14 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2072-6694 10.3390/cancers14051202 104101635 RAZ_Saba_Nabil_F._2022.pdf RAZ_Saba_Nabil_F._2022.pdf 1 AF0C5428649003138622ADB976FA449C d2ab30eaeec9d0bbe0dddd7150fbe2c9a755ae4df9e7946a74d99098949aa0ee c78e2abf-e70d-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=157144 https://www.mdpi.com/2072-6694/14/5/1202 0 db19dd4a-e70d-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=157145 Medicinska fakulteta 0 0 0